Jacobs Levy Equity Management, Inc Exelixis, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 472,820 shares of EXEL stock, worth $19.7 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
472,820
Previous 1,007,973
53.09%
Holding current value
$19.7 Million
Previous $44.4 Million
56.05%
% of portfolio
0.08%
Previous 0.18%
Shares
26 transactions
Others Institutions Holding EXEL
# of Institutions
695Shares Held
257MCall Options Held
1.51MPut Options Held
1.71M-
Black Rock Inc. New York, NY33.5MShares$1.4 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA26.1MShares$1.09 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA19.5MShares$812 Million3.48% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.5MShares$644 Million0.9% of portfolio
-
State Street Corp Boston, MA11.1MShares$463 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.4B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...